Whole Heart Radiotherapy for End-stage Heart Failure
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Mar 1, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
HEART FAILURE Heart Failure (HF) is a heterogeneous syndrome manifested by vascular congestion and/or peripheral hypoperfusion in the setting of structural and/or functional cardiac abnormalities. Congestion commonly presents with dyspnea, reduced exercise tolerance, and edema while hypoperfusion results in end-organ dysfunction. HF is a major public health problem and because of its age-dependent increase in incidence and prevalence, it's one of the leading causes of death and hospitalization among the elderly. As a consequence of the worldwide increase in life expectancy, and due to impro...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ≥ 18
- • End-stage heart failure with NYHA class 3 or 4,
- • LVEF ≤ 30%
- • NT-Pro-BNP ≥ 1500 pg/mL
- • on maximum medical therapy with progressive symptoms/disease as defined by their primary cardiologist and ineligible for advanced therapies including left ventricular assist devices and heart transplant
- Exclusion Criteria:
- • previous RT in the treatment field that precludes further RT
- • active connective tissue disease
- • interstitial pulmonary fibrosis
- • Participants who are unable to be positioned in a manner where treatment can be safely delivered
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Ian J Gerard, MD, PhD
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Tarek Hijal, MD
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Martin L Bernier, MD
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported